Moleculin Biotech's total assets for Q4 2024 were $16.93M, a decrease of -27.65% from the previous quarter. MBRX total liabilities were $10.95M for the fiscal quarter, a -31.22% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.